Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry.

Autor: Kojanova M; Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. martina.kojanova@vfn.cz., Turkova B; Value Outcomes, Prague, Czech Republic., Gkalpakiotis S; Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic., Cetkovska P; Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic., Fialova J; Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic., Dolezal T; Value Outcomes, Prague, Czech Republic., Machovcova A; Department of Dermatovenereology, University Hospital Motol, Prague, Czech Republic., Apol ED; LEO Pharma A/S, Ballerup, Denmark.
Jazyk: angličtina
Zdroj: Advances in therapy [Adv Ther] 2024 Oct; Vol. 41 (10), pp. 3951-3971. Date of Electronic Publication: 2024 Aug 29.
DOI: 10.1007/s12325-024-02952-4
Abstrakt: Introduction: The aim of this observational, multicenter study was to assess the real-world use of brodalumab for the treatment of moderate-to-severe plaque psoriasis in patients in the Czech Republic, using data from the BIOREP registry.
Methods: The study included 273 patients aged ≥ 18 years with moderate-to-severe psoriasis who received brodalumab. Endpoints were drug survival (time from treatment initiation to discontinuation), effectiveness [Psoriasis Area and Severity Index (PASI)], and health-related quality-of-life [Dermatology Life Quality Index (DLQI)].
Results: Predicted drug survival probability was 92.4% [95% confidence interval (CI): 89.1, 95.7%] at 6 months and 84.2% (95% CI 79.5, 89.1%) at 12 months; this was maintained at 24 months [80.4% (95% CI 74.5, 86.8%)]. Younger age, higher body mass index, and no previous biologic treatment were significantly associated with longer drug survival. Absolute PASI ≤ 3 after 3 months was achieved by 89.8% of patients; 92.4%, 77.8%, and 59.1% reached PASI 75, PASI 90, and PASI 100, respectively. After 12 months, 96.5% of 141 patients had an absolute PASI ≤ 3. The proportion of patients achieving DLQI 0/1 was 87.3% at 12 months.
Conclusion: This study demonstrated high and sustained drug survival with high rates of skin clearance and improved quality of life in patients with relatively severe disease treated with brodalumab. Improvements were observed as early as 3 months post-treatment initiation and were sustained for up to 24 months in a real-life setting.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: